Two‐year effectiveness and safety of golimumab in ulcerative colitis: An IG‐IBD study

BACKGROUND: Few data exist regarding the long‐term effectiveness of golimumab in ulcerative colitis. No data have been reported on real‐world continuous clinical response. OBJECTIVE: This study aimed to describe the long‐term outcomes in a large cohort of patients on golimumab who had ulcerative col...

Descripción completa

Detalles Bibliográficos
Autores principales: Pugliese, Daniela, Privitera, Giuseppe, Rogai, Francesca, Variola, Angela, Viola, Anna, Laterza, Lucrezia, Privitera, Antonino C., Allocca, Mariangela, Bossa, Fabrizio, Cappello, Maria, Daperno, Marco, Lorenzon, Greta, Mazzuoli, Silvia, Principi, Mariabeatrice, Sablich, Renato, Moser, Luisa, Ferronato, Antonio, Traini, Sara, Tapete, Gherardo, Bodini, Giorgia, Di Girolamo, Maria, Grossi, Laurino, Mocci, Giammarco, Ricci, Chiara, Saibeni, Simone, Festa, Stefano, Spagnuolo, Rocco, Cortelezzi, Claudio C., Mocciaro, Filippo, Rizzello, Fernando, Armuzzi, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259241/
https://www.ncbi.nlm.nih.gov/pubmed/33203342
http://dx.doi.org/10.1177/2050640620974308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259241/
https://www.ncbi.nlm.nih.gov/pubmed/33203342
http://dx.doi.org/10.1177/2050640620974308

Ejemplares similares